Synairgen PLC's (LON:SNG) Richard Marsden talks to Proactive London's Katie Pilbeam after revealing positive data from their phase II study on people with chronic obstructive pulmonary disease (COPD).
Marsden explains that this data reveals that their inhaled interferon beta drug, which was used on older patients is firstly safe and also works towards Synairgen's COVID-19 programme.
For Synaigen, the focus is on Covid-19 and to progress with SNG001 as a therapeutic for the virus, which means the COPD programme will remain paused for now.